优化接受依鲁替尼治疗的慢性淋巴细胞白血病患者结局:欧洲临床实践建议
欧洲血液学家专家组针对依鲁替尼治疗慢性淋巴细胞白血病(CLL)的临床实践问题提出管理建议,强调应监测治疗中出现的不良事件(多数轻微、短暂且多发生于治疗早期),通过正确剂量、提高警觉、缓解和管理不良事件来最大化患者结局。
要点
- 依鲁替尼治疗CLL需监测治疗中出现的不良事件,多数轻微、短暂且多发生于治疗早期。
- 即使面对更具挑战性的不良事件,通过仔细管理患者常可维持治疗且干扰最小。
- 推荐使用正确的依鲁替尼剂量,并提高对不良事件的警觉、缓解和管理以最大化结局。
核心结论
- 推荐使用正确的依鲁替尼剂量,并提高对不良事件的警觉、缓解和管理,以最大化接受依鲁替尼治疗的CLL患者结局。
研究设计与样本
- 欧洲血液学家专家组召开会议,识别与参与依鲁替尼治疗CLL患者治疗管理的医生相关的实际问题,并概述了 findings。
主要发现
- 近期数据提示依鲁替尼在临床实践中并非总能达到最优给药,剂量减少倾向增加且停药频率更高。
- 依鲁替尼治疗相关不良事件多数轻微、短暂且一般发生于治疗早期。
- 即使面对更具挑战性的不良事件,通过仔细管理患者常可维持治疗且干扰最小。
关键数值与推荐
- 推荐使用正确的依鲁替尼剂量。
- 推荐提高对不良事件的警觉、缓解和管理。
临床怎么用
- 应对接受依鲁替尼治疗的患者监测治疗中出现的不良事件。
- 通过仔细管理不良事件,即使更具挑战性的不良事件也常可维持治疗且干扰最小。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibrutinib is indicated in Europe for the treatment of several B-cell malignancies, including chronic lymphocytic leukaemia (CLL). However, despite the high efficacy and favourable toxicity profile of ibrutinib, recent data suggest that it is not always administered optimally in clinical practice, with an increased tendency for dose reduction and a higher frequency of discontinuation. An expert panel of European haematologists was convened to identify practical issues pertinent to physicians involved in the therapeutic management of ibrutinib-treated CLL patients and here we outline the findings. Practical management recommendations are given for treating patients with ibrutinib and clinical considerations for the management of adverse events (AEs) that can be associated with ibrutinib treatment are addressed. This article highlights that patients should be monitored for treatment emergent adverse events, most of which are mild, transient and generally occur early in therapy and that, even with more challenging AEs, patients can often be maintained on therapy with minimal disruption through careful management. The necessity to use the correct ibrutinib dose, along with increased awareness, vigilance, mitigation and management of AEs, are all recommended to maximise outcomes for CLL patients treated with ibrutinib.
引用
- Gribben JG, Bosch F, Cymbalista F, et al. Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice. Br J Haematol. 2018. PMID: 29318593. doi:10.1111/bjh.15080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。